Lilly’s New Obesity Drug Names Just Leaked? Meet Orfyzent and the Mysterious “Ret” Series

Original posted at obesity.news/ on Aug 26, 2025

Eli Lilly has quietly been laying the groundwork for what could be the most important drug names since Mounjaro and Zepbound. You’re hearing it first from On The Pen. Hat tip to Edward in our discord for doing the dirty work on this one. Buried in recent trademark filings are clues to how Lilly intends to brand two of its pipeline giants: Orforglipron and Retatrutide.

The first filing that jumped out is ORFYZENT, submitted by Lilly on April 23, 2024 and set to go live on April 22, 2025. The similarity between “Orfyzent” and Orforglipron is impossible to ignore. If confirmed, this would mark the official brand name for Lilly’s first oral GLP-1 therapy, a pill designed to go toe-to-toe with Novo Nordisk’s much-hyped oral semaglutide.

Then there’s Retatrutide, the once-weekly triple agonist that has generated enormous buzz for its weight loss results. Lilly filed multiple trademarks here, including RETZOUNDI and RETKOURO, both dated April 23, 2024. Notice the strategy—Lilly is playing off the branding cadence of Zepbound and Mounjaro. That “ReT” prefix locks in the Retatrutide identity, while the endings echo the same rhythm that’s already familiar to patients, prescribers, and insurers. It’s no accident. This is brand-building 101: take what works, and reinforce it with repetition.

Why does this matter? Because drug names are never random. They’re signals. Lilly is telling us how they want these medicines to be remembered, marketed, and trusted. Just as “Mounjaro” became synonymous with game-changing weight loss, Orfyzent may soon carry the promise of convenience, a daily pill that frees patients from injections. And Retzoundi or Retkouro? Those names are meant to echo loudly in the ears of doctors and patients who already know what Zepbound and Mounjaro can do.

This is the very first look at how Lilly likely plans to frame the future of obesity treatment in the U.S. and globally. If you’re reading this here, you’re ahead of the curve.

Stay tuned to OnThePen.com for more updates and in-depth analysis on the latest developments in weight loss and diabetes treatments. Sharing this article is a powerful form of advocacy that brings us closer to our goal of educating the masses and reducing the stigma of obesity. If you found this article insightful, please share it within your networks, especially in Facebook groups and Reddit forums dedicated to GLP-1 medications and diabetes management. Together, we can make a difference.

Also, in case you missed it, the podcast was a must listen today!

watch here!